Switch theme
Sign up to access all valuation multiples
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
2019
214
LTM Revenue $6.9M
LTM EBITDA -$177M
$24.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prime Medicine has a last 12-month revenue of $6.9M and a last 12-month EBITDA of -$177M.
In the most recent fiscal year, Prime Medicine achieved revenue of $3.0M and an EBITDA of -$196M.
Prime Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prime Medicine valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $3.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$187M | -$196M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -6582% | XXX | XXX | XXX |
| Net Profit | -$122M | -$198M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -6642% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Prime Medicine's stock price is $1.
Prime Medicine has current market cap of $174M, and EV of $24.8M.
See Prime Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.8M | $174M | XXX | XXX | XXX | XXX | $-1.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Prime Medicine has market cap of $174M and EV of $24.8M.
Prime Medicine's trades at 3.6x LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Prime Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Prime Medicine and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $24.8M | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -0.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPrime Medicine's NTM/LTM revenue growth is 194%
Prime Medicine's revenue per employee for the last fiscal year averaged $14K, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Prime Medicine's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Prime Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Prime Medicine and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6582% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -6388% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $14K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1682% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5206% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 6887% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prime Medicine acquired XXX companies to date.
Last acquisition by Prime Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Prime Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Prime Medicine founded? | Prime Medicine was founded in 2019. |
| Where is Prime Medicine headquartered? | Prime Medicine is headquartered in United States of America. |
| How many employees does Prime Medicine have? | As of today, Prime Medicine has 214 employees. |
| Who is the CEO of Prime Medicine? | Prime Medicine's CEO is Dr. Keith Gottesdiener, M.D.. |
| Is Prime Medicine publicy listed? | Yes, Prime Medicine is a public company listed on NAS. |
| What is the stock symbol of Prime Medicine? | Prime Medicine trades under PRME ticker. |
| When did Prime Medicine go public? | Prime Medicine went public in 2022. |
| Who are competitors of Prime Medicine? | Similar companies to Prime Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Prime Medicine? | Prime Medicine's current market cap is $174M |
| What is the current revenue of Prime Medicine? | Prime Medicine's last 12-month revenue is $6.9M. |
| What is the current EBITDA of Prime Medicine? | Prime Medicine's last 12-month EBITDA is -$177M. |
| What is the current EV/Revenue multiple of Prime Medicine? | Current revenue multiple of Prime Medicine is 3.6x. |
| What is the current EV/EBITDA multiple of Prime Medicine? | Current EBITDA multiple of Prime Medicine is -0.1x. |
| Is Prime Medicine profitable? | Yes, Prime Medicine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
